deal
Allergan acquires neurotoxin specialist Bonti in $195m deal
September 17, 2018Sales and Marketing Allergan, Bonti, Botox, Neurotoxin, acquisition, deal
The Dublin-headquartered multinational Allergan have agreed to acquire the clinical stage biotech Bonti in a deal worth more than $195 …
Novartis buys eczema drug in €95m deal
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, deal, eczema, experimental, patent
Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and …
Senate claims Novartis misled public on Trump lawyer deal
July 16, 2018Sales and Marketing Novartis, Senate, Trump, United States, deal
A report released by the United States Senate has found that Novartis’ relationship with Donald Trump’s long-time lawyer Michael Cohen …
Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports
July 15, 2016Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal
Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal
July 6, 2016Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer
Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …
Novartis signs $150 million deal with Xencor to develop bispecific antibodies
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial
Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …
Shire completes Baxalta takeover
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales
UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT). The …
Monsanto rejects Bayer’s $62 billion offer
May 25, 2016Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto
World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) …
Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal
May 19, 2016Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results
Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …
Biogen signs $2 billion partnership deal with UPenn for gene therapies
May 17, 2016Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research
Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …
Sanofi Files Hart-Scott-Rodino notification for Medivation acquisition
May 13, 2016Medical Communications, Sales and Marketing M&A, MA, Medivation, Sanofi, deal
French drugmaker Sanofi (Euronext: SAN) on Friday said it has filed a premerger notification with the US Department of Justice Antitrust …
Sanofi makes unsolicited $9.8 billion bid for Medivation
April 28, 2016Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer
French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …
Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics
Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
Pfizer to call off $160 billion merger with Allergan
April 6, 2016Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation
US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
AstraZeneca completes respiratory deal with Almirall
November 3, 2014Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, deal, duaklir, merger, respiratory
AstraZeneca has finally completed its takeover of Almirall’s respiratory drug portfolio in a deal worth $875 million. As reported by …
Latest content
FibroFind appoints Lee Borthwick as CEO
